

Reconsideration of the application is respectfully requested.

I. AMENDMENT

Please make the following amendments:

In the Claims:

Please cancel claim 43 without prejudice or disclaimer.

Please add the following new claims 44-64:

505
C17
B1
--44. An intravascular device for use with a catheter having a detachment apparatus, said device comprising:

at least one lead element; and

a trailing element detachably interconnected to at least one said lead element, said trailing element adapted for attachment to said detachment apparatus;

wherein said at least one lead element is capable of causing occlusion of a vessel.

2 45. The intravascular device of claim 44, wherein said at least one lead element comprises a material capable of producing thrombosis.

3 46. The intravascular device of claim 44, wherein said at least one lead element comprises an expandible element.

4 47. The intravascular device of claim 44, wherein said at least one lead element comprises a particle.

5 48. The intravascular device of claim 44, wherein said at least one lead element comprises a coil.

6 49. The intravascular device of claim 44, wherein said trailing element is chemically detachable from said at least one lead element.

7 50. The intravascular device of claim 44, wherein said trailing element is mechanically detachable from said at least one lead element.

B' 8 51. The intravascular device of claim 44, wherein said at least one lead element functions as an anchoring element.

9 52. The intravascular device of claim 44, further comprising a fiber detachably interconnecting said at least one lead element and said trailing element.

10 53. The intravascular device of claim 44, wherein the end of said detachment apparatus has the shape of a loop, and wherein said trailing element comprises a hook adapted to engage said loop.

11 54. The intravascular device of claim 53, wherein said at least one lead element comprises a coil.

12/ 55. An intravascular device comprising:

at least one lead element;

a trailing element; and

a fiber detachably interconnecting the trailing element to said at least one lead element;

wherein said at least one lead element is capable of causing occlusion of a vessel.

B' 13/ 12/ 56. The intravascular device of claim 55, wherein said at least one lead element comprises a material capable of producing thrombosis.

14/ 12/ 57. The intravascular device of claim 55, wherein said at least one lead element comprises a coil.

15/ 12/ 58. The intravascular device of claim 55, wherein said at least one lead element functions as an anchoring element.

16/ 59. An intravascular device for use with a catheter having a detachment apparatus, said device comprising:

at least one lead element;

a trailing element; and

a fiber detachably interconnecting the trailing element to said at least one lead element;

wherein said at least one lead element is capable of causing occlusion of a vessel, and
wherein said trailing element is adapted for attachment to said detachment
apparatus.

17/ 60. The intravascular device of claim 59, wherein said at least one lead element comprises a material capable of producing thrombosis. 16/

18/ 61. The intravascular device of claim 59, wherein said at least one lead element comprises a coil. 16/ *B1 concl.*

19/ 62. The intravascular device of claim 59, wherein said at least one lead element functions as an anchoring element. 16/

20/ 63. The intravascular device of claim 59, wherein the end of said detachment apparatus has the shape of a loop, and wherein said trailing element comprises a hook adapted to engage said loop. 16/

21/ 64. The intravascular device of claim 63, wherein said at least one lead element comprises a coil.-- 20/

Support for new claims 44-64 may be found throughout the specification and in the claims as originally filed. No new matter is added.

II. RESPONSE TO OFFICE ACTION

Claim 43 has been canceled. New claims 44-64 have been added. Claims 44-64 are pending. Support for the amendments to the claims is found throughout the specification and in the claims as originally filed (for example, *see* page 18, line 9 to page 20, line 5; and FIG. 12). No new matter is added.

A. The 35 U.S.C. § 112, Second Paragraph Rejection

The Examiner has rejected claim 43 under 35 U.S.C. § 112, second paragraph. Applicant has canceled claim 43, rendering the Examiner's rejection moot.

To further point out and distinctly claim the subject matter which the Applicant regards as his invention, Applicant has added claims 44-64 which recite an intravascular device comprising at least one lead element detachably interconnected to a trailing element, wherein the lead element is capable of causing occlusion of a vessel.

The above amendments are believed to meet the Examiner's concern. Therefore, in view of these amendments, favorable reconsideration is requested.

B. The Rejection of Claim 43 as Anticipated under 35 U.S.C. § 102(b) by Lahille *et al.* is Moot

The Examiner has rejected claim 43 as being anticipated under 35 U.S.C. § 102(b) by U. S. Patent No. 4,957,501 to Lahille *et al.* Applicant has canceled claim 43, rendering the Examiner's rejection moot.

New independent claims 44, 55 and 59 recite an intravascular device comprising at least one lead element detachably interconnected to a trailing element, the lead element capable of causing occlusion of a vessel.

To support a rejection under § 102(b), the cited prior art must disclose each and every element of the rejected claim. In this regard, Applicant notes that Lahille *et al.* do not disclose a lead element capable of causing occlusion of a vessel. Thus independent claims 44, 55 and 59, as well as the claims depending therefrom, are not anticipated by Lahille. In addition, the dependent claims include additional limitations that further distinguish them from Lahille.

Furthermore, claims 44-64 are not obvious over Lahille *et al.* Lahille *et al.* relates to a filter device that “is particularly for implantation in the interior vena cava ... to arrest the migration of all thrombi of dangerous size” (*see* Abstract), and Lahille *et al.* state that this occurs “without interrupting the blood flow rate, the filter itself not being thrombogenic” (*see* col. 7, lines 15-20). In contrast, the subject claims recite at least one lead element detachably interconnected to a trailing element, the lead element capable of causing occlusion of a vessel. Therefore, not only does Lahille *et al.* teach away from the occlusive or thrombosis-producing capability recited in the subject claims, but use of occlusive or thrombosis-causing elements would render the device of Lahille *et al.* unsuitable for its intended purpose.

In summary, Applicant respectfully submits that the present invention is not anticipated nor obvious over the cited art and that claims 44-64 are in condition for allowance. Favorable reconsideration is requested.